NOX4 and systemic sclerosis: Analyses of human dermal fibroblasts (HDFs) from patients with systemic sclerosis confirmed the expression of Nox4, whereas Nox1 and Nox2 were not detectable, indicating that Nox4 targeting is a promising future treatment for fibrotic skin diseases [9].